Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Cancer. 2010 Mar 1;116(5):1165-76. doi: 10.1002/cncr.24862.
Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL. Cancer 2010. (c) 2010 American Cancer Society.
急性淋巴细胞白血病(ALL)是造血母细胞的克隆性扩增,是一种高度异质性的疾病,包含许多实体,针对这些实体采用了不同的治疗策略。尽管 ALL 在儿科肿瘤学中是一个成功的范例,但成人的结果却落后于儿童。新药物的扩展、更可靠的免疫和分子技术用于评估微小残留病以及更精确的风险分层的努力,正在为成人 ALL 治疗带来新的方面。在这篇综述中,作者总结了有关 ALL 生物学和治疗的相关和最新文献,并讨论了当前治疗成人 ALL 的策略和新方法的潜在影响。癌症 2010. (c)2010 美国癌症协会。